The above-named tumor harboring the double p.L858R/p.T790M EGFR-mutation, did not respond to erlotinib, while another case with p.L858R did, despite concurrently harboring the p.G12V KRAS-mutation and p.R158L TP53-mutation. This evidence concerns the gene EGFR and neoplasm.